Evidence map›Paper›PMID 37775605›Full record

ArticleDiscover nano2023

Multimodal imaging and photothermal/chemodynamic therapy of cervical cancer using GSH-responsive MoS

Runrun Shao, Xiaofang Qiao, Linlin Cao, Jianliang Man, Lingyun Guo, Lanlan Li, Wen Liu, Lihong Li, Bin Wang, Lixia Guo and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover nano, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Runrun ShaoCollege of Basic Medicine University, Shanxi Medical Univerity, Taiyuan, 030000, People's Republic of China.
Xiaofang QiaoHenan Center for Drug Evaluation and Inspection, Henan, 450000, People's Republic of China.
Linlin CaoHenan Center for Drug Evaluation and Inspection, Henan, 450000, People's Republic of China.
Jianliang ManCollege of Basic Medicine University, Shanxi Medical Univerity, Taiyuan, 030000, People's Republic of China.
Lingyun GuoCollege of Basic Medicine University, Shanxi Medical Univerity, Taiyuan, 030000, People's Republic of China.
Lanlan LiCollege of Basic Medicine University, Shanxi Medical Univerity, Taiyuan, 030000, People's Republic of China.
Wen LiuCollege of Basic Medicine University, Shanxi Medical Univerity, Taiyuan, 030000, People's Republic of China. liuwen@sxmu.edu.cn.
Lihong LiCollege of Basic Medicine University, Shanxi Medical Univerity, Taiyuan, 030000, People's Republic of China.
Bin WangCollege of Basic Medicine University, Shanxi Medical Univerity, Taiyuan, 030000, People's Republic of China.
Lixia GuoCollege of Basic Medicine University, Shanxi Medical Univerity, Taiyuan, 030000, People's Republic of China.
Sufang MaCollege of Basic Medicine University, Shanxi Medical Univerity, Taiyuan, 030000, People's Republic of China.
Boye ZhangCollege of Basic Medicine University, Shanxi Medical Univerity, Taiyuan, 030000, People's Republic of China.
Haojiang WangCollege of Basic Medicine University, Shanxi Medical Univerity, Taiyuan, 030000, People's Republic of China.
Lili YanCollege of Basic Medicine University, Shanxi Medical Univerity, Taiyuan, 030000, People's Republic of China. yanlili@sxmu.edu.cn.
Shanxi Medical University · CNHenan Provincial Center for Disease Control and Prevention · CN

Funding

Science Foundation of Shanxi Province 202203021211236
6 · The paper itself

Abstract

The development of nanoparticles capable of inducing reactive oxygen species (ROS) formation has become an important strategy for cancer therapy. Simultaneously, the preparation of multifunctional nanoparticles that respond to the tumor microenvironment is crucial for the diagnosis and treatment of tumors. In this study, we designed a Molybdenum disulfide (MoS

Indexed as

Chemodynamic therapyGSH responsiveMR/CT imagingTumor microenvironment

Identifiers

PMID37775605
PMCPMC10541390
OpenAlexW4387167608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.